ANGEL OPARA: Open Payments
NPI 1710669072 · FRANKFORT, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$968 in 51 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $818 · 2025 $968
Food & beverage: $968
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $323 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $264 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Vanda Pharmaceuticals Inc. | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Corium, LLC | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Alkermes, Inc. | 1 | $31 |
| Neurocrine BioSciences, Inc. | 1 | $18 |
Products named: VRAYLAR, CAPLYTA, Auvelity, FANAPT, TRINTELLIX, Azstarys, REXULTI, Qelbree.
Industry payments across KY — which companies pay providers there.
